Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, has completed a $15 million capital raise led by Van Tuyl Companies, with participation from existing investors Zoetis and Mayo Clinic. The investment supports Techcyte’s path to profitability and continued expansion of its Fusion platform across veterinary, environmental, and human diagnostic segments.
Techcyte’s veterinary business is currently profitable, and the company expects its environmental and human segments to reach profitability by next year. The raise also includes access to Mayo Clinic’s Safe Harbor dataset of more than 17 million de-identified slides and pathology reports, which will be used to enhance Techcyte’s AI capabilities within the Fusion platform.
Diagnostic laboratories worldwide face increasing pressure to deliver accurate results while managing constrained resources, rising test volumes, and ongoing workforce shortages. Techcyte’s Fusion platform addresses these challenges by integrating AI, digitized workflows, and interoperability with laboratory systems to streamline case review, standardize processes, and enable more scalable diagnostic operations.
Support: Canaccord Genuity served as exclusive advisor to Techcyte on the transaction.
KEY QUOTE:
“Laboratories are being asked to do more with less, while maintaining high standards for quality and rapid turnaround times. Techcyte Fusion directly addresses these challenges through unified AI-enabled pathology workflows. This investment allows us to continue growing the Fusion platform and extending the world-class capabilities that were built in collaboration with Mayo Clinic.”
Ben Cahoon, CEO, Techcyte
